Gabriel Leung Sells 5,000 Shares of Novocure Ltd (NASDAQ:NVCR) Stock

Novocure Ltd (NASDAQ:NVCR) Director Gabriel Leung sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $64.83, for a total value of $324,150.00. Following the transaction, the director now owns 74,504 shares of the company’s stock, valued at $4,830,094.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gabriel Leung also recently made the following trade(s):

  • On Wednesday, June 19th, Gabriel Leung sold 25,000 shares of Novocure stock. The stock was sold at an average price of $60.02, for a total value of $1,500,500.00.
  • On Monday, June 10th, Gabriel Leung sold 5,000 shares of Novocure stock. The stock was sold at an average price of $55.05, for a total value of $275,250.00.
  • On Friday, May 10th, Gabriel Leung sold 5,000 shares of Novocure stock. The stock was sold at an average price of $49.79, for a total value of $248,950.00.

Shares of NASDAQ NVCR traded down $0.26 during trading hours on Friday, reaching $68.88. The stock had a trading volume of 719,273 shares, compared to its average volume of 675,572. The stock has a fifty day moving average price of $58.02. The company has a current ratio of 4.73, a quick ratio of 4.39 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $6.26 billion, a P/E ratio of -99.83 and a beta of 2.44. Novocure Ltd has a twelve month low of $26.02 and a twelve month high of $69.59.

Novocure (NASDAQ:NVCR) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $73.31 million during the quarter, compared to analyst estimates of $72.85 million. Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Novocure’s revenue was up 40.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.23) earnings per share. Research analysts predict that Novocure Ltd will post -0.17 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. raised its stake in shares of Novocure by 2.5% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 20,991 shares of the medical equipment provider’s stock valued at $703,000 after purchasing an additional 513 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in Novocure by 4.1% during the first quarter. Rice Hall James & Associates LLC now owns 15,215 shares of the medical equipment provider’s stock worth $733,000 after acquiring an additional 600 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Novocure by 2.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 35,980 shares of the medical equipment provider’s stock worth $1,733,000 after acquiring an additional 1,020 shares in the last quarter. PRW Wealth Management LLC acquired a new position in Novocure during the fourth quarter worth $36,000. Finally, Steinberg Global Asset Management raised its stake in Novocure by 1.0% during the first quarter. Steinberg Global Asset Management now owns 136,765 shares of the medical equipment provider’s stock worth $6,588,000 after acquiring an additional 1,371 shares in the last quarter. Institutional investors and hedge funds own 65.34% of the company’s stock.

NVCR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novocure in a report on Sunday, May 26th. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a report on Friday, May 24th. Wedbush set a $79.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Friday, May 24th. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Oppenheimer started coverage on Novocure in a research note on Friday, June 28th. They issued an “outperform” rating and a $75.00 target price for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Novocure presently has a consensus rating of “Buy” and a consensus target price of $52.44.

Novocure Company Profile

Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.

Read More: When is a capital gain realized?

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.